AstraZeneca Expands Rare Disease Pipeline with Amolyt Pharma Acquisition
AstraZeneca has announced it is set to acquire Amolyt Pharma, a French clinical-stage biotechnology company focused on developing novel treatments
Read moreAstraZeneca has announced it is set to acquire Amolyt Pharma, a French clinical-stage biotechnology company focused on developing novel treatments
Read moreAmerican clinical-stage biotechnology company Vaxart, Inc. has announced that the United States Biomedical Advanced Research and Development Authority (BARDA) granted
Read moreLutathera®, developed by Swiss drugmaker Novartis has demonstrated a substantial 72% reduction in the risk of disease progression or death
Read moreAbbVie has introduced PRODUODOPA® (foslevodopa/foscarbidopa) in the European Union to address advanced Parkinson’s disease. AbbVie (NYSE: ABBV) recently announced the
Read moreBristol Myers Squibb has added a premier radiopharmaceutical platform to its portfolio with the acquisition of RayzeBio, a radiopharmaceutical therapeutics
Read moreAmerican multinational pharmaceutical company Bristol Myers Squibb and Karuna Therapeutics, Inc. (“Karuna”) have announced that they have entered into a
Read moreAstraZeneca announced it has agreed to acquire Gracell Biotechnologies Inc, which is set to advance its cell therapy portfolio across
Read moreIn a significant development for the fight against advanced small cell lung cancer (SCLC), the U.S. Food and Drug Administration
Read moreAbbVie is set to acquire ImmunoGen in a $10.1B deal which encompasses ImmunoGen’s first-in-class antibody-drug conjugate (ADC) cancer treatment ELAHERE®
Read moreBoehringer Ingelheim has confirmed the acquisition of T3 Pharmaceuticals AG, a Swiss clinical-stage biotech company thereby expanding its immuno-oncology portfolio.
Read more